Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTXNASDAQ:CAPSNASDAQ:KRBPNASDAQ:TFFP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.82+4.6%$3.52$1.51▼$27,200.00$99K1.6786,369 shs30,584 shsCAPSCapstone$1.91-2.1%$2.09$1.58▼$16.18$307K-0.82719,952 shs71,710 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289K1.07762,748 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt+4.60%+13.04%-21.21%-92.04%-99.99%CAPSCapstone-2.05%+15.06%-5.91%+190,999,900.00%+190,999,900.00%KRBPKiromic BioPharma0.00%0.00%0.00%-87.00%-93.33%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxt0.8744 of 5 stars0.04.00.00.03.10.00.6CAPSCapstoneN/AN/AN/AN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/ACAPSCapstone 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$133.99K0.77N/AN/A$2,687.49 per share0.00CAPSCapstone$43.42M0.01N/AN/AN/A∞KRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/ATFFPTFF Pharmaceuticals-$70.98K-4.07N/AN/A$4.04 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$32.38MN/A0.00∞N/AN/A-439.07%-122.96%N/ACAPSCapstoneN/AN/A0.00∞N/AN/AN/AN/AN/AKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/A-1,596.64%-310.17%-196.06%N/ALatest ADTX, CAPS, KRBP, and TFFP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ACAPSCapstoneN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.090.08CAPSCapstoneN/AN/AN/AKRBPKiromic BioPharmaN/A0.160.22TFFPTFF PharmaceuticalsN/A0.890.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%CAPSCapstone2.55%KRBPKiromic BioPharma10.91%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%CAPSCapstone42.80%KRBPKiromic BioPharma20.59%TFFPTFF Pharmaceuticals4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt6057,00014.23 millionNo DataCAPSCapstone38158,000N/AN/AKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableADTX, CAPS, KRBP, and TFFP HeadlinesRecent News About These CompaniesTFF Pharmaceuticals approves dissolution planMarch 8, 2025 | uk.investing.comTFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC DeregistrationFebruary 6, 2025 | prnewswire.comTFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True PotentialDecember 12, 2024 | bovnews.comThe TFFP Stock Mystery: Why Did TFFP Plunge Today?December 6, 2024 | bovnews.comTFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?November 23, 2024 | bovnews.comStock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?November 20, 2024 | bovnews.comTFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock MovementsNovember 19, 2024 | bovnews.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?November 15, 2024 | bovnews.comTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 15, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals to Dissolve and Liquidate AssetsNovember 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of OperationsNovember 14, 2024 | quiverquant.comTFF Pharmaceuticals Announces It Will Wind Down OperationsNovember 14, 2024 | globenewswire.comTFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comTFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's WhyOctober 8, 2024 | zacks.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | finanznachrichten.deTFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | markets.businessinsider.comPost-COVID Trends in Biopharma Contract ManufacturingSeptember 25, 2024 | contractpharma.comThe Yadot Group to Acquire Experiential Agency Socials DallasSeptember 16, 2024 | dallasinnovates.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative Gains5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsBy Thomas Hughes | May 14, 2025View 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears5 Mid-Cap Stocks Insiders Are Buying This YearBy Thomas Hughes | April 29, 2025View 5 Mid-Cap Stocks Insiders Are Buying This Year3 Stocks Just Announced Intentions to Buyback Near 10% of SharesBy Leo Miller | April 28, 2025View 3 Stocks Just Announced Intentions to Buyback Near 10% of SharesADTX, CAPS, KRBP, and TFFP Company DescriptionsAditxt NASDAQ:ADTX$1.82 +0.08 (+4.60%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.82 +0.00 (+0.27%) As of 05:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Capstone NASDAQ:CAPS$1.91 -0.04 (-2.05%) As of 05/22/2025 04:00 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.TFF Pharmaceuticals NASDAQ:TFFP$0.06 0.00 (0.00%) As of 04/10/2025TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
